In 2024, the global glioblastoma multiforme (GBM) treatment market was valued at USD 2.84 billion, and under prevailing pipelines and investment assumptions the market is forecast to grow at a compound annual growth rate (CAGR) of 9.5 % over the coming decade. This robust expansion reflects intensifying R&D in neuro-oncology, growing incidence of GBM globally, and regulatory impetus for...